Phase II study of nivolumab (anti-PD1), tadalafil, and oral vancomycin in patients with refractory primary hepatocellular carcinoma or liver dominant metastatic cancer from colorectal or pancreatic cancers.

Changqing Xie,Donna Mabry-Hrones,Bradford J. Wood,Seth M. Steinberg,David E. Kleiner,Tim F. Greten

Phase II study of nivolumab (anti-PD1), tadalafil, and oral vancomycin in patients with refractory primary hepatocellular carcinoma or liver dominant metastatic cancer from colorectal or pancreatic cancers.

2020

Changqing Xie
Donna Mabry-Hrones
Bradford J. Wood
Seth M. Steinberg
David E. Kleiner
Tim F. Greten

TPS4656Background: Treatment options for advanced hepatocellular carcinoma (HCC) and liver dominant metastatic disease from colorectal or pancreatic cancers are limited with poor overall survival. ...

Keywords:

Oral vancomycin
Oncology
Cancer
in patient
Internal medicine
Pathology
Nivolumab
Tadalafil
Hepatocellular carcinoma
Refractory
Phases of clinical research
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations